No Data
No Data
Tianjin Lisheng Pharmaceutical's H1 Attributable Profit, Revenue Grow
Tianjin Dev (00882.HK): tianjin lisheng pharmaceutical's net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.
On August 23, Tianjin Development (00882.HK) announced that Tianjin Lisheng Pharmaceutical (002393.SZ) achieved revenue of 0.745 billion yuan (RMB) in the first half of 2024, a year-on-year increase of 13.25%; the net income attributable to shareholders of Tianjin Lisheng Pharmaceutical was 0.102 billion yuan, a year-on-year increase of 13.50%; and the basic earnings per share was 0.40 yuan.
Tianjin Lisheng Pharmaceutical: Summary of Half-Year Report in 2024.
Tianjin Lisheng Pharmaceutical: Half-year report for the year 2024.
Tianjin Lisheng Pharmaceutical (002393.SZ): Net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.
Tianjin Lisheng Pharmaceutical (002393.SZ) announced its interim report for the first half of 2024, with revenue of 0.745 billion yuan, a year-on-year increase of 13.25%; net income attributable to shareholders of listed companies was 0.102 billion yuan, a year-on-year increase of 13.50%; net income attributable to shareholders of listed companies excluding non-recurring gains and losses was 99.1793 million yuan, a year-on-year increase of 11.72%; basic earnings per share were 0.40 yuan.
Tianjin Lisheng Pharmaceutical (002393.SZ) produces vitamin products such as vitamin B1 tablets, vitamin B2 tablets, vitamin B6 tablets, complex vitamin B tablets, vitamin C tablets, etc.
Tianjin Lisheng Pharmaceutical (002393.SZ) stated on its investor platform that the company produces various vitamin products, including vitamin B1 tablets, vitamin B2 tablets, vitamin B6 tablets, complex vitamin B tablets, and vitamin C tablets. All these products are branded under the famous Chinese brand 'San Yu' and have a reliable quality, achieving extensive market recognition for many years. Subsidiary Central Pharmaceutical Industry also produces varieties such as vitamin E soft capsules. With the current production capacity of the company and its subsidiaries, the market needs can be fully met.
No Data
No Data